Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis

Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasing...

Full description

Bibliographic Details
Main Authors: Del Corso Lisette, Balleari Enrico, Arboscello Eleonora, Ghio Riccardo, Mencoboni Manlio, Racchi Omar
Format: Article
Language:English
Published: Hindawi Limited 2013-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2013/520712
id doaj-98a573e5b99342b5a7f7331c47f81820
record_format Article
spelling doaj-98a573e5b99342b5a7f7331c47f818202020-11-24T22:34:57ZengHindawi LimitedCase Reports in Hematology2090-65602090-65792013-01-01201310.1155/2013/520712520712Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary MyelofibrosisDel Corso Lisette0Balleari Enrico1Arboscello Eleonora2Ghio Riccardo3Mencoboni Manlio4Racchi Omar5Department of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, ItalyDepartment of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, ItalyDepartment of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, ItalyDepartment of Hematology and Oncology, IRCCS AOU San Martino-IST, Largo Rosanna Benzi 10, 16132 Genoa, ItalyDepartment of Oncology, Villa Scassi Hospital, ASL 3, Corso Scassi, 16151 Genoa, ItalyDepartment of Oncology, Villa Scassi Hospital, ASL 3, Corso Scassi, 16151 Genoa, ItalyPrimary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasingly used in order to prevent IOL in this setting. Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL.http://dx.doi.org/10.1155/2013/520712
collection DOAJ
language English
format Article
sources DOAJ
author Del Corso Lisette
Balleari Enrico
Arboscello Eleonora
Ghio Riccardo
Mencoboni Manlio
Racchi Omar
spellingShingle Del Corso Lisette
Balleari Enrico
Arboscello Eleonora
Ghio Riccardo
Mencoboni Manlio
Racchi Omar
Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
Case Reports in Hematology
author_facet Del Corso Lisette
Balleari Enrico
Arboscello Eleonora
Ghio Riccardo
Mencoboni Manlio
Racchi Omar
author_sort Del Corso Lisette
title Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_short Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_full Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_fullStr Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_full_unstemmed Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis
title_sort mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis
publisher Hindawi Limited
series Case Reports in Hematology
issn 2090-6560
2090-6579
publishDate 2013-01-01
description Primary myelofibrosis (PMF) is a myeloproliferative neoplasm frequently complicated by transfusion dependent anemia. Both anemia and transfusion-dependence are associated with a poor outcome, at least in part because of toxic effects of iron overload (IOL). Iron-chelating therapy (ICT) is increasingly used in order to prevent IOL in this setting. Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL.
url http://dx.doi.org/10.1155/2013/520712
work_keys_str_mv AT delcorsolisette mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT ballearienrico mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT arboscelloeleonora mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT ghioriccardo mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT mencobonimanlio mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
AT racchiomar mayorerythropoieticresponseafterdeferasiroxtreatmentinatransfusiondependentanemicpatientwithprimarymyelofibrosis
_version_ 1725725503021645824

Similar Items